Skip to main content

Table 2 Univariate analysis of locoregional control (LRC)

From: Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers

  At 1 year (%) At 3 years (%) P
Radiochemotherapy regimen
 Cisplatin weekly (N = 75) 70 58  
 Cisplatin 100 mg/m2 (N = 58) 85 78 0.010
Age
 ≤56 years (N = 67) 78 65  
 ≥57 years (N = 66) 74 68 0.72
Gender
 Female (N = 29) 92 87  
 Male (N = 104) 72 61 0.010
ECOG Performance score
 0–1 (N = 115) 78 69  
 2 (N = 18) 66 49 0.14
Primary tumor site
 Oropharynx (N = 69) 83 74  
 Hypopharynx (N = 19) 47 47  
 Larynx (N = 30) 79 67  
 Oral cavity/Floor of mouth (N = 15) 75 56 0.047
T-category
 T1–2 (N = 16) 93 76  
 T3–4 (N = 117) 74 65 0.28
N-category
 N0-2a (N = 66) 76 68  
 N2b-3 (N = 67) 76 65 0.93
Histologic grading
 G 1–2 (N = 85) 77 69  
 G3 (N = 48) 75 63 0.65
Cumulative cisplatin dose
 ≤200 mg/m2 (N = 85) 70 62  
 >200 mg/m2 (N = 48) 86 74 0.09
  1. After Bonferroni correction for multiple tests, p-values of <0.006 were considered significant